ImmunoPrecise Antibodies (IPA) to Release Quarterly Earnings on Monday

ImmunoPrecise Antibodies (NASDAQ:IPA) will likely be announcing its Q1 2026 results before the market opens on Monday, September 15th. Analysts expect the company to announce earnings of ($0.04) per share and revenue of $5.90 million for the quarter. Investors may visit the the company’s upcoming Q1 2026 earningresults page for the latest details on the call scheduled for Monday, September 15, 2025 at 10:30 AM ET.

ImmunoPrecise Antibodies (NASDAQ:IPA) last announced its earnings results on Tuesday, July 29th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.02). The company had revenue of $5.06 million for the quarter, compared to the consensus estimate of $7.89 million. ImmunoPrecise Antibodies had a negative net margin of 122.10% and a negative return on equity of 40.62%. On average, analysts expect ImmunoPrecise Antibodies to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

ImmunoPrecise Antibodies Trading Up 8.5%

IPA opened at $2.10 on Monday. The company has a current ratio of 2.08, a quick ratio of 1.85 and a debt-to-equity ratio of 0.49. The firm has a market cap of $96.68 million, a price-to-earnings ratio of -3.08 and a beta of 0.53. ImmunoPrecise Antibodies has a 12 month low of $0.27 and a 12 month high of $3.25. The stock has a fifty day moving average price of $1.98 and a 200-day moving average price of $1.03.

Wall Street Analyst Weigh In

Separately, Wall Street Zen upgraded shares of ImmunoPrecise Antibodies from a “sell” rating to a “hold” rating in a report on Saturday, August 2nd. Two investment analysts have rated the stock with a Buy rating, According to MarketBeat, ImmunoPrecise Antibodies currently has an average rating of “Buy” and an average target price of $4.00.

Institutional Trading of ImmunoPrecise Antibodies

A hedge fund recently raised its stake in ImmunoPrecise Antibodies stock. XTX Topco Ltd increased its holdings in shares of ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) by 394.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 91,382 shares of the company’s stock after purchasing an additional 72,897 shares during the period. XTX Topco Ltd owned approximately 0.20% of ImmunoPrecise Antibodies worth $97,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 6.70% of the company’s stock.

ImmunoPrecise Antibodies Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.